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Patient-derived in vivo models of human cancer have become a reality, yet their turnaround
time is inadequate for clinical applications. Therefore, tailored ex vivo models that faithfully
recapitulate in vivo tumour biology are urgently needed. These may especially benefit the
management of pancreatic ductal adenocarcinoma (PDAC), where therapy failure has been
ascribed to its high cancer stem cell (CSC) content and high density of stromal cells and
extracellular matrix (ECM). To date, these features are only partially reproduced ex vivo
using organoid and sphere cultures. We have now developed a more comprehensive and
highly tuneable ex vivo model of PDAC based on the 3D co-assembly of peptide amphiphiles
(PAs) with custom ECM components (PA-ECM). These cultures maintain patient-specific
transcriptional profiles and exhibit CSC functionality, including strong in vivo tumourigenicity.
User-defined modification of the system enables control over niche-dependent phenotypes
such as epithelial-to-mesenchymal transition and matrix deposition. Indeed, proteomic
analysis of these cultures reveals improved matrisome recapitulation compared to organoids.
Most importantly, patient-specific in vivo drug responses are better reproduced in self-
assembled cultures than in other models. These findings support the use of tuneable self-
assembling platforms in cancer research and pave the way for future precision medicine
approaches.
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W ith a 5-year survival of 10%, pancreatic ductal ade-nocarcinoma (PDAC) remains a leading cause ofcancer-related death worldwide1. The intrinsic resis-
tance of PDAC tumours is compounded by intratumour and
interpatient heterogeneity, as well as extrinsic factors, such as
pronounced desmoplasia and hypovascularization, which limit
the efficacy of existing treatments, such as gemcitabine,
nab-paclitaxel and FOLFIRINOX2. The development of more
effective therapies, tailored to individual patients, may benefit
from the use of platforms that incorporate patient-derived cells
for predictive drug testing. Patient-derived xenografts (PDX) in
mice have shown great promise in their ability to reproduce
patient response3, but their establishment takes months, which
hampers their use in the context of PDAC, where median overall
survival is only 6 months. Thus, faster and more scalable ex vivo
platforms are required for the establishment of clinically useful
patient-specific models of pancreatic cancer.
Current ex vivo platforms allow cell cultures in 3D, either
floating or embedded in biomimetic matrices. Floating spheroid
cultures are a simple and popular 3D approach4. However, the
lack of matrix attachment, artificially high nutrient gradients,
variable growth patterns and limited control over cell distribution
make nonadherent spheroid cultures less desirable than matrix-
based approaches like Matrigel, decellularized tissues or custom
hydrogels5. Matrigel, although routinely used for organoid and
organotypic cultures6, is limited by its murine origin, undefined
composition and batch-to-batch variability7. Similarly, decel-
lularized tissues suffer from high complexity and poor
tractability8. In contrast, hydrogels based on synthetic polymers,
such as polyethylene glycol, offer great flexibility in the control of
their physicochemical properties9, while being less biocompatible
than hydrogels based on natural materials. Ex vivo platforms
based on hybrid biomaterials, such as methacrylated
hyaluronan10 and gelatin methacryloyl11, have shown excellent
physical tuneability, but have limitations in mimicking biological
signals other than hyaluronan and gelatin (denatured collagen).
Advances in biofabrication, such as 3D printing12 and micro-
fluidic systems13 have enabled control over PDAC culture
microarchitecture and fluid flow, respectively. Nevertheless, these
models still lack the capacity to recreate the diverse and dense
PDAC stroma at the nanoscale with custom physical properties
and composition.
More recently, various types of self-assembling peptides have
been developed for the ex vivo modelling of tissues with enhanced
versatility14–16. These peptides offer the possibility to bioengineer
complex microenvironments through a reductionist approach,
controlling nanoscale geometries and the presentation of epitopes
to selectively signal cells17. Peptide amphiphiles (PAs) are a class
of self-assembling peptides capable of generating nanofibrous
hydrogels that can recreate the architecture of the natural extra-
cellular matrix (ECM)18. PAs can be designed to bind selectively
and nonselectively to molecules while assembling into high-
aspect-ratio cylindrical micelles (nanofibres) in polar solutions.
To enhance the molecular complexity and biological relevance of
these matrices, we have established methodologies to use PAs to
co-assemble with and organise ECM macromolecules and other
proteins, such as keratins19 into hydrogel matrices with tuneable
signalling capabilities20, structures21,22 and physical properties23.
Notably, recreation of functional tumour niches requires a more
complex, diverse and dynamic organisation of ECM components,
which is not currently attainable with most ex vivo tumour
models (Supplementary Table 1).
In this work, we use a multicomponent self-assembling
approach to establish an instructive matrix (PA-ECM) com-
posed of PA molecules and multiple ECM components of PDAC,
including collagen type I, fibronectin, laminin and hyaluronan.
Through the immediate presentation of these macromolecules as
both the structural and signalling components of the hydrogel, we
expect to promote niche-dependent phenotypes associated with
poor prognosis, including cancer stem cell (CSC) propagation,
epithelial-to-mesenchymal transition (EMT) and ECM deposi-
tion. We hypothesise that a CSC-supportive environment will
enable a more faithful approximation of the patients’ PDAC
characteristics than directed differentiation via growth factors (as
in organoids). To recapitulate the tumour microenvironment, we
include patient-derived pancreatic stellate cells (PSCs) and pri-
mary macrophages, which are the key cellular components of the
PDAC stroma24. As biological references for the validation of our
self-assembling platform, we use patient-matched tumour tissue
and PDXs, and we also benchmark our findings against patient-
matched 2D monolayers, Matrigel-embedded organoids and
sphere cultures.
Results
Construction of co-assembled PA-ECM matrices for PDAC cell
culture. While current in vitro models of PDAC are characterised
by a relatively simple design that restricts control over the phy-
sical properties and composition of the microenvironment, PA
molecules can be co-assembled with ECM macromolecules to
form tuneable matrices for cell culture (Fig. 1a). The fibrillar
nature of this model was verified by electron microscopy
(Fig. 1b–e). Upon co-assembly, PA fibres form highly aligned
bundles whose arrangement varies according to the composition
of the ECM: PA-collagen hydrogels exhibit thicker fibrils
(Fig. 1c), while the addition of fibronectin results in thinner, more
aligned mesh-like structures (Fig. 1d). Similar structures were
observed when PAs are co-assembled with collagen, fibronectin,
laminin and hyaluronan (Fig. 1e), which we subsequently used as
our standard PA-ECM hydrogels. On average, PA fibres were
approximately 20 × 300 nm in size (Fig. 1f), similar to most ECM
proteins like collagen25. The β-sheet conformation of the
assembled fibres was confirmed by circular dichroism spectro-
scopy (Fig. 1g). In terms of stiffness, the Young’s modulus of PA-
ECM co-assembled hydrogels was around 1 kPa, which is within
the range of pancreatic PDX tissues (Fig. 1h), as well as published
data for primary PDAC26, while Matrigel, used for the generation
of organoids, was much softer than PDAC tissue at around 90 Pa.
Due to the heterogeneous nature of the PDAC stroma, some
tumour areas exhibit a higher stiffness of up to 20 kPa. This can
be recreated in the PA-ECM system by modifying peptide or
gelling agent (e.g., collagen or CaCl2) concentration, PA-
macromolecule affinity19 or the peptide sequence27. Further-
more, given the inherent anisotropy of PDAC stroma, mechanical
properties will depend on the type of measurement performed
(e.g., tension, compression). In this study, we have conducted
indentation measurements via an atomic force microscope as it
has been used extensively to describe mechanical properties of
tumours28. Our experimental approach to benchmark PA-ECM
hydrogels against organoids and other in vitro platforms as
models for PDAC is outlined in Fig. 1i.
To validate the platform for cell culture, we generated 3D co-
cultures of patient-derived primary PDAC cells and stromal cells,
which we encapsulated in PA-ECM hydrogels (Fig. 2a). Cell
encapsulation was verified by microscopy (Fig. 2b). Over time,
PDAC cells formed duct-like colonies amid extensive stroma
(Fig. 2c). After 14 days, these cultures remained highly viable, as
indicated by live/dead staining (Fig. 2d), and proliferative, as
evidenced by Ki-67 staining (Fig. 2e; Supplementary Fig. 1a, b).
Average colony diameter after 7 days was consistent in PA and
PA-ECM (58 µm) and, by day 21, it increased a further 10 µm in
PA-only gels and 20 µm in PA-ECM (Supplementary Fig. 1c, d).
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Colony number and size were highly patient-specific and did
not increase with higher ratios of stromal cells (Supplementary
Fig. 1e, f). PDAC and stromal cells intermingled throughout
the co-assembled matrices, maintaining their usual morphologies
—elongated PSCs and rounded macrophages (Fig. 2f–i). In 2D,
spheres and collagen gels, colonies were generally solid,
without lumina. This contrasts with PA-ECM and organoid
colonies, which were predominantly hollow or toroidal
(Supplementary Fig. 1g, h), thereby preserving the topology of
pancreatic ducts.
Ex vivo models of PDAC are transcriptionally distinct. To
explore the overall differences between PA-ECM cultures and
current in vitro models of PDAC (2D monolayers, Matrigel-
embedded organoids and floating spheres), we analysed mono-
cultures of patient-derived cancer cells by RNA-seq and
compared the results to their corresponding primary and PDX
tumours. All ex vivo cultures clustered by patient (Fig. 3a), which
indicates that patient-specific transcriptional programs were
maintained. Although overall gene expression was similar in vivo
and ex vivo (Fig. 3b), there was a notable distance between the
Fig. 1 Design and characterisation of PA-ECM co-assembling matrices. a Schematic illustration of PA hydrogel co-assembly with ECM macromolecules
compared to currently used substrates for the in vitro modelling of PDAC. b Transmission electron micrograph of PA fibres. Scale bar: 100 µm.
c–e Scanning electron micrographs of PA hydrogels co-assembled with collagen (c), collagen and fibronectin (d) and all ECM components (e); insert
indicates imaged area within a 2 µL hydrogel. Scale bar: 2 µm. Insert scale bar: 500 µm. f PA fibre size measured from TEM micrographs. Box plots indicate
range, interquartile range and median. n= 20 individual fibres. g PA fibre circular dichroism spectrum in HEPES buffer. h Stiffness (Young’s modulus) of
PDX tissue, as measured by atomic force microscopy (n= 71 measurements across a tissue section), compared to PA-ECM (n= 24 measurements of a
10mg/mL gel) and Matrigel (n= 38 measurements of a 10 mg/mL gel), as measured by rheometry. Box plots indicate range, interquartile range and
median. i Experimental outline for the validation of the platform as a model for pancreatic cancer.
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tumour samples and the monocultures (Fig. 3a; Supplementary
Fig. 2a). This may reflect gene expression from other cell types
within the tumour microenvironment. Analysis of differential
expression between PA-ECM cultures and primary tumours
confirmed that this difference was largely due to the higher
expression of interstitial matrix proteins and other stromal factors
in the primary tissue samples (Fig. 3c). This was also observed
when comparing organoids to primary samples (Supplementary
Fig. 2b). Interestingly, differential expression analysis between the
3D models and 2D monolayers revealed enrichment in receptor-
binding matrix components, as well as hyaluronan regulators, in
PA-ECM hydrogels (Fig. 3d). Moreover, PA-ECM cultures
favoured the basal (or squamous) PDAC subtype, which corre-
sponded to the patients’ primary tumours analysed in this study
(Supplementary Fig. 2c–d), while spheres were highly enriched in
the classical (or pancreatic progenitor) subtype. Both PA-ECM
cultures and spheres were highly enriched in the pancreatic CSC
signature recently identified by Lytle et al.29 (Supplementary
Data 1), while organoids showed negative enrichment, suggestive
of a more differentiated phenotype (Fig. 3d; Supplementary
Fig. 2e). PA-ECM cultures were also enriched in genes involved in
oxidative phosphorylation, a hallmark of pancreatic CSCs30.
Linear regression revealed that cancer cell-specific signatures,
especially the CSC signature, were strongly correlated between
primary tumours and their ex vivo models, while matrix com-
ponents were only weakly correlated, especially the core ECM
(Fig. 3e). Overall, 15 out of 21 correlations were stronger for PA-
ECM cultures than for organoids. Interpatient differences in CSC
marker expression were also reflected better in PA-ECM cultures
than in other ex vivo models (Supplementary Fig. 2f). Taken
together, these findings suggest that self-assembled PDAC cul-
tures in PA-ECM maintain the transcriptional cancer (stem) cell
Fig. 2 PA-ECM cultures for the ex vivo modelling of pancreatic cancer. a Schematic illustration of 3D cell culture in PA-ECM. b Brightfield micrograph of
PDAC cells co-cultured with PSCs and macrophages in PA-ECM; insert indicates imaged area within a 5 µL hydrogel. Scale bar: 50 µm. Insert scale bar:
500 µm. c Haematoxylin (blue) and eosin (red) stain of PA-ECM hydrogel triple culture. Scale bar: 50 µm. d 3D projection of PDAC cells grown in PA-ECM
for 14 days. Living cells were stained with calcein AM (green) and dead cells with ethidium homodimer (red). Scale bar: 100 µm. e 3D projection of PDAC
cells co-cultured with PSCs and macrophages in PA-ECM hydrogels for 7 days and stained for EpCAM (green) and Ki-67 (white). Scale bar: 100 µm. f–i 3D
projection of a PA-ECM hydrogel triple culture. PDAC cells were identified by EpCAM (green)(f), PSCs by α-SMA (magenta) (g) and macrophages by
CD68 (cyan) (h) immunostaining. All cell types are shown on (i). Scale bars: 50 µm.
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signatures of the corresponding human tumours, while matri-
some components are relatively underrepresented in the absence
of stromal cells.
PA-ECM cultures contain functional CSCs. To ascertain that
there is a more appropriate representation of CSCs in PA-ECM
cultures compared to other models, stemness marker expression
was validated by qPCR and flow cytometry. Compared to 2D
monolayers, there was a twofold increase in the expression of the
stemness-related transcription factors SOX2 and KLF4 in PA-
ECM cultures (Fig. 4a) and a much higher proportion of
CD133+ /CXCR4+ cells than in spheres or organoids, which
falls in the range of matched PDX tumours (Fig. 4b; Supple-
mentary Fig. 3a). Functionally, the high CSC content of PA-ECM
cultures translated into an increased rate of sphere formation
compared to cells harvested from monolayer, organoid or pri-
mary sphere cultures (Fig. 4c). To confirm that these cultures
maintained their tumorigenic potential, we implanted PA-ECM
cultures and organoids subcutaneously into the flanks of nude
mice. Implanted PA-ECM cultures resulted in a higher and
accelerated engraftment rate compared to implanted organoids
(Fig. 4d). Faster growth and larger tumour volumes were achieved
by increasing the number of cells encapsulated in the implanted
PA-ECM hydrogels (Fig. 4e). These implants grew comparatively
faster than their corresponding PDX models (Supplementary
Fig. 3b). For the same number of implanted cells, PA-ECM cul-
tures resulted in tumours that were four times larger than those
derived from organoids (Fig. 4e). The histological make-up of the
tumours was also distinct. Those grown from PA-ECM implants
were poorly differentiated like their primary tumour, with few
discernible epithelial structures. In contrast, organoid-derived
tumours were more well-differentiated and arranged into more
organised duct-like epithelia (Fig. 4f; Supplementary Fig. 3c).
Moreover, the matrix composition of the tumours was different,
as shown by pentachrome staining: PA-ECM culture–derived
tumours presented abundant collagen (shown in red) among the
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Fig. 3 Transcriptomic analysis of ex vivo models of PDAC. a Hierarchically clustered distance matrix of the PDAC samples analysed by RNA sequencing.
Distance is shown in colour-coded arbitrary units. b Regularised log2 expression of the top 20,000 genes expressed in all samples. c Volcano plot showing
gene enrichment in primary tumours compared to PA-ECM monocultures, with correction for interpatient differences. d Heatmap depicting pathways
identified by gene set enrichment analysis that are up- or downregulated in 3D models with respect to 2D monolayers. Normalised enrichment scores
(NES) are colour-coded. e Correlation of epithelial and matrisome gene list expression between primary PDAC tissues and their corresponding organoids
and PA-ECM cultures. Mean and range are shown for two biologically independent replicates per sample type. ORG organoids, SPH spheres, PRI primary
tumours.
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localised to the stromal interface, mostly away from the cancer
cells, and there were multiple mucinous cores (sulphated glycans
in violet). These findings suggest that PDAC cells expanded as
PA-ECM cultures and organoids differ significantly in their
degree of differentiation, which is likely to impact interactions
between the cancer cells and the surrounding stroma.
Increased control over cellular phenotypes in PA-ECM
hydrogels. A key advantage of PA-ECM hydrogels is their tune-
ability, which enables separate control over their physical
properties and composition, thereby facilitating the study of phe-
notypic responses to specific stimuli. To illustrate this, we inves-
tigated the cellular plasticity of PDAC cultures in PA-ECM
hydrogels. Since cellular plasticity is one of the hallmarks of
CSCs31, we hypothesised that cultures in self-assembling hydrogels
would more readily acquire mesenchymal characteristics upon
stimulation. To test this, we cultured PDAC cells in PA-only
hydrogels of increasing fibre density as a strategy to mechanically
promote EMT. This resulted in the upregulation of canonical
EMT markers, such as vimentin and MMP14, as well as their
upstream transcription factors ZEB1 and SNAI2 (Fig. 5a). At the
Fig. 4 CSC enrichment in PA-ECM cultures. a Expression of CSC factors by PDAC cells (12560) cultured in PA-ECM compared to 2D monolayers
(mean ± SD; n= 3 biological replicates). b Percentage of CD133+ /CXCR4+ PDAC cells in PDX and ex vivo PDAC models as assayed by flow cytometry
in three matched experiments (mean ± SD). c Number of spheres by size range formed by PDAC cells (12560) derived from PA-ECM cultures, primary
spheres, organoids and 2D monolayers (mean ± SD; n= 3 biological replicates). d Engraftment rate of PA-ECM and organoid PDAC cultures (12560)
implanted in nude mice (three mice with two tumours per condition). e Volume of tumours grown in nude mice from implanted PA-ECM and organoid
cultures carrying increasing numbers of PDAC cells (12560) (three mice with two tumours per condition). Shaded areas denote standard deviation around
mean. f Representative histology images of PDAC tissues derived from patient 12560, including primary tumour, patient-derived xenografts and tumours
grown in nude mice from implanted PA-ECM and organoid cultures. Scale bars: 100 µm.
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protein level, the number of vimentin-positive colonies was
increased (Fig. 5b), as was the total amount of vimentin (Supple-
mentary Fig. 4a). These findings are in line with the observation
that high epithelial vimentin correlates with densely packed
fibrillar ECM in PDAC32. Increasing cell density had a similar
effect (Supplementary Fig. 4b), which suggests analogous
mechanotransduction. Unlike MMP14, other ECM regulators like
periostin and TIMP1 were downregulated in PDAC cells
(Fig. 5a). In contrast, all three were upregulated in PSCs (Sup-
plementary Fig. 4c, d), hinting at cell-lineage-specific differences in
mechanotransduction.
Next, we hypothesised that modifying the composition of the
gelling solution, as well as the medium, would enable control
over the expression of niche-dependent genes. Indeed, PA-ECM
co-assembled cultures displayed a clear upregulation of various
ECM receptors (ITGB1, CD44s, CD44v6) and regulators (MMP14,
LOXL2) compared to PA-only gels assembled in ECM-free CaCl2
solutions (Fig. 5c). Vimentin expression was increased in PA-only
hydrogels, which can be rationalised by the crosslinking ability of
CaCl2 resulting in the formation of more rigid hydrogels. We
then used conditioned medium from primary PSCs as a model of
paracrine stimulation and also observed an upregulation of genes
involved in ECM remodelling and EMT (Fig. 5d), which was not
observed in spheres or organoids (Supplementary Fig. 4e). On the
other hand, conditioned medium from PDAC cells upregulated
the expression of collagens in self-assembled PSC monocultures,
enhancing the effects observed in 2D (Supplementary Fig. 4f). We
also investigated macrophage cultures, whose gene expression
Fig. 5 Control over PDAC cell phenotypes in PA hydrogels. a Gene expression of PDAC cells (12560) as a function of PA concentration relative to 2D
controls (mean ± SD; n= 3 biological replicates). p values were calculated by two-way ANOVA with Bonferroni correction. b Percentage of vimentin-
positive PDAC colonies (12560) as a function of PA concentration as quantified from immunofluorescence micrographs. Box plots indicate range,
interquartile range and median (n= 8 biological replicates). p values were calculated by one-way ANOVA with Bonferroni correction. c Log2 normalised
expression of PDAC cells (12560) grown in PA hydrogels assembled in different gelling conditions relative to the 2D baseline (mean ± SD; n= 3 biological
replicates). p values were calculated by two-way ANOVA with Bonferroni correction. d Log2 normalised gene expression of PDAC cells (12560) cultured in
PA hydrogels in sphere medium (SM) and PSC-conditioned medium (PCM) relative to the 2D SM baseline (mean ± SD; n= 3 biological replicates). p
values were calculated by two-way ANOVA with Bonferroni correction. e Scratch closure of PDAC cells (12560) cells in the presence of hyaluronan. Box
plots indicate range, interquartile range and median (n= 12 biological replicates in three experiments). f Log2 normalised invasion of PDAC cells (12560)
across collagen-coated transwells as a function of the concentration of low (10 kDa) and high (1 MDa) molecular mass hyaluronan. Box plots indicate
range, interquartile range and median (n= 42 biological replicates in 6 experiments). p values were calculated by one-way ANOVA with Bonferroni
correction. g Number of spheres formed by PDAC cells (12560) as a function of the size and concentration of hyaluronan in the medium (mean ± SD; n= 6
biological replicates in three experiments). p values were calculated by two-way ANOVA with Bonferroni correction. h Brightfield images of PDAC cell
colonies (12560) formed on low-attachment plates coated with collagen, with and without 10 kDa/1 MDa hyaluronan in the medium. Scale bars: 500 µm.
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upon polarisation with CSF1 was found to resemble that of
tumour-associated macrophages from PDAC tumours (Supple-
mentary Fig. 5a). Macrophages thrived as self-assembled mono-
cultures (Supplementary Fig. 5b) and, upon exposure to both the
PDAC and PSC-derived conditioned media, they exhibited a
modified cytokine profile, particularly by upregulating IL6
(Supplementary Fig. 5c), which was validated by ELISA
(Supplementary Fig. 5d). These paracrine effects may explain
the relative proximity of macrophages to PDAC colonies in co-
cultures in PA-ECM (Supplementary Fig. 5e).
We next specifically investigated the ECM polysaccharide
hyaluronan as a proven critical component of PDAC33.
Hyaluronan is highly abundant in the PDAC stroma (Supple-
mentary Fig. 5f) and is known to upregulate key CSC- and EMT-
related genes, such as ZEB134 and NANOG35. PA-ECM cultures
with hyaluronan revealed that these previously reported tran-
scriptional effects are size- and concentration-dependent (Sup-
plementary Fig. 5g). Functionally, hyaluronan did not stimulate
migration in 2D (Fig. 5e), but it did so in 3D in a size- and
concentration-dependent manner (Fig. 5f; Supplementary Fig. 5h)
and also enhanced sphere formation (Fig. 5g). Strikingly, the
combination of both low- and high-molecular-mass hyaluronan
resulted in the highest increase in sphere formation, which
supports the previously proposed notion of synergistic effects
between both forms of hyaluronan on PDAC cells36. Such
combination was able to rescue sphere formation in PDAC cells
seeded in suspension on collagen-coated plates, which otherwise
form semi-adherent monolayers (Fig. 5h). These effects could be
mediated by CD44, which is one of the most widely expressed
hyaluronan receptors in PDAC and a known CSC marker,
although other receptors such as HMMR could also play a role.
These findings highlight the regulatory functions that hyaluronan
exerts on PDAC cells and how these can be dissected in PA-ECM
hydrogels according to features such as polymer size and
concentration.
Multicellular PA-ECM cultures enhance PDAC matrisome
recapitulation. Despite the inclusion of hyaluronan, collagen,
laminin and fibronectin in our custom ECM, many core matrix
proteins remained underrepresented in PA-ECM monocultures,
as shown in Fig. 3c. In PDAC, the primary source of ECM is the
stromal compartment, which, instructed by the PDAC cells, pro-
duces large quantities of diverse matrix proteins24. Thus, to
enhance the ex vivo recapitulation of the stroma of our platform,
we created multicellular PA-ECM cultures by also incorporating
primary PSCs and macrophages (triple cultures), as described
above (Fig. 2a). Preliminary analysis by ELISA showed that both
PA-ECM and organoid cultures secreted a variety of cytokines, of
which IL-6 and CCL2 were the most abundant in triple cultures
compared to monocultures (Supplementary Fig. 5d). Matrix
deposition by multicellular PA-ECM cultures and organoids was
quantified by mass spectrometry and compared to that of corre-
sponding primary and PDX tumours. The abundance and com-
position of the matrisome of the primary tumours was
considerably heterogeneous, which was also reflected by both the
PDX and ex vivo models (Supplementary Data 2). In particular,
the least differentiated tumours (12560 and 12707) presented the
most abundant matrisomes both in vivo and ex vivo (Supple-
mentary Fig. 6a, b; Supplementary Data 2). For all primary
tumours, collagens were the most abundant proteins (Supple-
mentary Fig. 6c), especially collagen type I (Supplementary
Fig. 6d), while glycoproteins and proteoglycans were less abundant
and had a more variable distribution (Supplementary Fig. 6e, f),
which was validated by immunohistochemistry (Supplementary
Fig. 7).
Comparison between the top matrisome proteins from in vivo
and ex vivo samples revealed a rich basement membrane in both
PA-ECM cultures and organoids and a moderate underrepre-
sentation of interstitial matrix proteins ex vivo (Fig. 6a). This
highlights the inherent limitations of short-term cultures for the
modelling of fibrotic tissues, since the bulk of interstitial matrix
deposition and remodelling occurs as a long-term process
complemented by the daily turnover of a much smaller sacrificial
ECM pool37. This notion is further supported by the observation
that ex vivo models are richer in collagen type III than type I
(Fig. 6b), which is characteristic of early ECM deposition during
wound healing and fibrosis. Despite this limitation, PA-ECM
cultures exhibited very high fibrillar collagen abundance, while
Matrigel-embedded organoids were comparatively deficient in
collagen type I, the most abundant matrisome protein in all
primary tumour samples. As for the main proteins of the
basement membrane, laminins, PA-ECM cultures presented a
very similar composition to primary tissues, while organoids
differed significantly (Fig. 6b). For example, laminin 111, a key
constituent of Matrigel, makes up 90% of the laminins in
organoid cultures, but less than 1% in primary tissues. This is due
to the fact that, in humans, laminin 111 is not expressed
postnatally in most tissues, including the pancreas38, and
therefore does not constitute a representative ECM protein for
the modelling of PDAC and other tissues.
These observations are in agreement with recently published
data39 and expand on those findings by showing that patients
with highly abundant ECMs also harbour the most diverse
matrisomes (Fig. 7a). In consequence, we hypothesised that
patients would cluster according to their overall matrisome
content and this was indeed the case (Fig. 7b). When analysing
the total number of detected proteins by linear regression, both
the PA-ECM cultures and organoids were predictive of overall
ECM content, while PDX models were less reliable due to the
large number of murine ECM proteins (Fig. 7c). Further analysis
of the origin of matrisome proteins from the PDX and organoid
models revealed that over 50% of core ECM proteins were of
mouse origin (Fig. 7d). These were mostly interstitial ECM
proteins such as fibronectin, fibrinogen and periostin for PDX
tumours, whereas most murine proteins in organoids were
basement membrane constituents of Matrigel. Due to this
overrepresentation of basement membrane proteins in organoids,
the core ECM abundance correlations with the corresponding
primary tumours were much weaker than those observed for PA-
ECM cultures (Fig. 7e; Supplementary Fig. 8). These differences
in correlation with patient-specific matrisomes are in line with
the transcriptomic data shown in Fig. 3e, i.e., primary tumours
with low ECM content (12556) show stronger correlation with
the respective ex vivo models than those primary tumours with
high ECM content (12560). The stronger correlations observed
between the primary tumours and the PA-ECM models
compared to the corresponding organoids are also found in both
transcriptomic and proteomic datasets, which clearly indicates
that PA-ECM cultures enhance matrisome recapitulation.
In vivo drug responses are reproduced in self-assembled PDAC
cultures. Since both CSCs and the abundant matrix are known to
contribute to therapy resistance in PDAC24,40, and PA-ECM
cultures recapitulate these features more closely than organoids,
we hypothesised that they should also better reflect in vivo drug
response. PA-ECM cultures are amenable to analysis of drug
response by histology, which enables the quantification of cellu-
larity, and by immunohistochemistry, which enables the quanti-
fication of proliferative and apoptotic cells by staining for Ki-67
and cleaved caspase-3, respectively (Fig. 8a). In order to
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benchmark ex vivo drug responses, we used in vivo responses of
PDX tumours to gemcitabine/nab-paclitaxel (a standard-of-care
treatment for PDAC) as a reference. We selected patients whose
PDX models exhibited characteristically low, moderate and high
sensitivity to chemotherapy (Fig. 8b). We then quantified the
response of the corresponding PDAC mono- and multicellular
cultures in PA-ECM hydrogels to gemcitabine/nab-paclitaxel
(Fig. 8c). As expected, the highest rate of apoptosis and lowest
proliferation was observed in the most chemosensitive patient,
12707, while the opposite was observed for the most resistant
patient, 12556. The patient exhibiting moderate chemosensitivity,
12560, also showed an intermediate response ex vivo.
Interestingly, the inclusion of PSCs and macrophages in these
cultures resulted in a decrease in the rate of apoptosis, but did not
alter cell proliferation, which suggests that stromal cells promote
cell-intrinsic chemoresistance, as previously reported41. When we
doubled the number of incorporated PSCs, there was a
proportional decrease in the number of apoptotic cells, which
further supports this notion. Moreover, qualitative analysis of
responses to a variety of chemotherapeutic agents showed a larger
number of resistant colonies in multicellular cultures compared to
monocultures (Supplementary Fig. 9a). This difference could even
be observed for cultures treated with the potent diterpenoid
triptolide, whose prodrug minnelide is currently in clinical testing
(NCT03117920). An alternative method for assessing PDAC drug
response in PA-ECM is the quantification of the tetrasaccharide
CA19-9, which is used as a circulating biomarker to track tumour
burden and drug response in PDAC patients42. However, we
found no correlation between secreted CA19-9 and response to
treatment for any of our tested ex vivo models (Supplementary
Fig. 9b). Of note, one of the analysed tumours did not produce
any CA19-9, a condition known as Lewis-negative, which further
limits the relevance of this method.
Instead, to more accurately and mechanistically quantify
treatment responses, we assayed cell cycle profiles in various
ex vivo conditions. This should provide early evidence of
response to both the gemcitabine and nab-paclitaxel, as these
result in cell cycle arrest in M and G2 phase, respectively. Thus,
the number of viable cells remaining in G1 upon treatment
should constitute a suitable surrogate marker for drug response
and therefore correlate with the in vivo PDX tumour volume
following treatment. Intriguingly, only PA-ECM cultures con-
sistently reproduced the in vivo response, while spheres and 2D
monolayers actually showed the opposite response pattern
(Fig. 8d). For organoids, response was variable and did not
correlate with the in vivo data. Examination of the cell cycle
profiles of ex vivo cultures revealed enhanced resistance in PA-
ECM gels, denoted by a higher proportion of treated cells in G1
for all tested tumours (Fig. 8e–f). When PSCs were incorporated
into these cultures, they remained present in higher numbers in
PA-ECM gels than in 2D or organoids after 10 days in culture
(Supplementary Fig. 9c), which suggests that PA-ECM hydrogels
enhanced the proliferation and/or viability of stromal cells. Upon
treatment with gemcitabine/nab-paclitaxel, PSCs showed a
further three-fold enrichment in all conditions, which indicates
resistance to cell cycle arrest.
However, when cultures were treated with triptolide, both PSCs
and PDAC cells were eradicated. PDAC monocultures treated
with triptolide showed large differences in response between the
resistant and sensitive patients, with both the PA-ECM and
organoids most closely reproducing the in vivo response
(Supplementary Fig. 9d). Interestingly, while response to
Fig. 6 Core matrisome recapitulation in PDX, PA-ECM and organoid models. a Heatmap of the top matrisome proteins detected which fall on or above
the 90th percentile rank in abundance (mean across all patients) in at least one of the sample categories. For the PDX and Matrigel samples, abundance
was calculated as the sum of the human and murine peptides. Those proteins for which >50% of the peptides detected were of murine origin are indicated
with an asterisk. b Distribution of interstitial collagen chains and laminin trimers for all sample categories. Data correspond to the mean across all patients.
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gemcitabine/nab-paclitaxel seemed to correlate with the propor-
tion of CSCs in culture, response to triptolide did not correlate
with the presence of CSCs (Supplementary Fig. 9e). These data
are not in line with the concept that triptolide specifically targets
CSCs43, which was proposed based on studies using immortalised
cell lines. Instead our results suggest that triptolide efficiently
targets both the CSC and non-CSC. Overall, our findings indicate
that primary PA-ECM cultures mimic in vivo drug responses and
may constitute a useful platform for ex vivo drug testing and to
investigate the specific dependencies and mechanisms of
resistant cells.
Discussion
Over the past decade, increasing interest in the ex vivo recapi-
tulation of in vivo tumour biology and stem cell niches has
spurred the development of organoid cultures to model malig-
nancies such as PDAC44. Although organoids constitute a very
useful model of ductal differentiation, PDAC cells in such cul-
tures are dependent on a diverse cocktail of factors originally
identified in the intestinal crypt, such as R-spondin and noggin,
with unclear relevance for PDAC. These factors promote the self-
renewal of cells expressing LGR545, but CSCs in PDAC do not
seem to express LGR546. This may explain, at least in part, our
finding that CSC content in organoids was significantly lower
than in PA-ECM cultures and spheres. On the other hand, self-
assembling hydrogels have been widely used to recreate normal
stem cell niches for the modelling of neurogenesis47,
osteogenesis48 and chondrogenesis49, often incorporating ECM
molecules such as heparin50 and hyaluronan51. Here we show
that more comprehensive PA-ECM hydrogels can be employed to
mimic key features of the PDAC microenvironment in a defined
manner, resulting in cultures that are enriched in highly
tumourigenic CSCs. As proof of concept, we show that the
expression of EMT markers and functional responses, such as 3D
migration and sphere formation can be modulated by controlling
specific properties of the hydrogels, such as fibre density or the
size and concentration of hyaluronan, which has long been sus-
pected of promoting cancer stemness33. In addition, the co-
assembled PA-ECM hydrogels provide a fibrillar microenviron-
ment with tuneable alignment. Such anisotropic arrangement of
ECM fibres is commonly observed in PDAC tumours and
appears to correlate with poor prognosis32.
We expect that future studies will shed more light on the exact
composition of the pancreatic CSC niche, which remains
Fig. 7 In vivo and ex vivo PDAC matrisome analysis. a Scatter plot showing the total abundance and number of proteins of each matrisome category for
each primary tumour analysed. b Principal component analysis of the core matrisome datasets from patients 12556, 12559, 12560, 12707 and 12975.
c Scatter plot showing the correlation between the number of proteins of the primary core matrisomes and those of their corresponding PDX, PA-ECM and
organoid models. The PDX murine baseline indicates the number of murine ECM proteins predicted to reside at the site of PDX implantation. d Percentage
of matrisome peptides detected in the PDX and organoid samples which are of human, mouse or common origin. Common peptides are identical in both
species. e Colour-coded correlation between the core matrisome protein abundances in primary tumours and their corresponding PDX, PA-ECM and
organoid models. R is the correlation coefficient.
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unknown despite several promising studies31,52,53. Large-scale
transcriptomic analysis of PDAC primary tumours has shown
that laminin-332 has the highest hazard ratio among all matri-
some proteins39. Notably, this matrix protein was highly abun-
dant in PA-ECM cultures, whereas organoids are dominated by
laminin-111, which is rarely found in primary tumours. More-
over, while the core matrisome of PA-ECM cultures reflected the
fibrotic status of the corresponding primary tumours, organoid
cultures contained very little collagen type I, despite it being the
main component of the PDAC matrisome. Thus, the skewed
Fig. 8 PDAC treatment response in PA-ECM and organoid cultures. a Histology of PDAC (12560) mono- and triple cultures in PA-ECM treated with
gemcitabine/nab-paclitaxel. Cells were stained with H&E to assess cellularity, Ki-67 for proliferation and cleaved caspase-3 for apoptosis. Scale bars:
100 µm. b In vivo response of PDX tumours to chemotherapy depicted as percentage of tumour volume post-treatment relative to controls (0.9% NaCl).
Box plots indicate range, interquartile range and median. For each patient and condition, n= 5 mice with one tumour each. c Quantification of Ki-67 and
cleaved caspase-3 staining of PDAC mono- and triple cultures in PA-ECM treated with gemcitabine/nab-paclitaxel. Triple+ cultures contained twice the
number of PSCs (mean ± SD; n= 3 biological replicates). d Response of PA-ECM and organoid cultures to gemcitabine/nab-paclitaxel as assayed by flow
cytometry. Percentages represent the proportion of cells that were both intact and in G1 phase compared to untreated controls (mean ± SD; n= 5 biological
replicates). e, f Flow cytometry plots showing the cell cycle arrest of PA-ECM (e) and organoid (f) cultures treated with gemcitabine/nab-paclitaxel. The
upper panels show the gated populations of intact cells. The lower panels depict the cell cycle profiles of untreated (red) and treated (blue) samples gated
to exclude debris and doublets.
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ECM composition and the inadequate softness of Matrigel
hampered a sufficient recapitulation of the PDAC matrisome,
which only recently was shown to correlate with progression39
and poor prognosis54. Furthermore, the defined composition of
PA-ECM hydrogels and the use of primary stromal cells instead
of immortalised cell lines such as PS1 and THP-1 improve upon
the design of previous studies55 and enhance the clinical ade-
quacy of the platform. In the context of in vivo studies, PA-ECM
hydrogels appear to be a suitable carrier for tumour implantation
and may be considered as an alternative to Matrigel. Methodo-
logical improvements such as orthotopic implantation and the
use of humanised mice could further strengthen its use, especially
in translational studies.
The interplay between niche-dependent phenotypes, such as
stemness, EMT, fibroblast activation and ECM deposition has
been recognised as a critical factor in PDAC chemoresistance24.
Accordingly, comprehensive bottom-up approaches like ours are
necessary to accurately reflect clinical responses56. Indeed, drug
sensitivity for established cell lines and traditional 2D cultures
rarely correlates with clinical responses, while 3D hydrogel cul-
tures often exhibit more authentic responses57–59. Consistently,
our data show that neither 2D cultures nor spheres grown in
suspension were able to accurately reflect the in vivo response of
PDX models. On the other hand, PA-ECM cultures faithfully
reproduced the in vivo response when assessed as cytotoxicity
and cell cycle arrest. Overall, organoids exhibited a weaker cor-
relation, which may be related to their reduced CSC content and
insufficient recapitulation of the PDAC matrisome. Although our
data suggest that PA-ECM hydrogels represent a useful platform
for drug testing using patient-derived cells, studies with larger
cohorts and a wider distribution of tumour stage, site and sam-
pling technique (resection, solid and liquid biopsy) will be
required to fully establish this platform in the preclinical arena.
More exhaustive studies should also determine whether optimi-
sation of our tuneable self-assembling approach is necessary to
more closely match certain biological features such as tumour
grade and subtype. Whereas such optimisation is generally not
possible with substrates like Matrigel due to their reduced tract-
ability, it is allowed by the modular nature of our system,
including the customisation of the ECM, cellular ratios and
medium composition, as well as the physical properties of the co-
assembled hydrogels. However, we hypothesise that major
adaptations of the system may not be needed given the observed
maintenance of patient-specific transcriptomic, proteomic and
drug response signatures.
Another important aspect to consider for preclinical imple-
mentation is scalability, which is also facilitated by the wide range
of hydrogel volume (1–100 µL) and peptide concentration
(1–20 mg/mL) at which this platform can operate. Lower volumes
might be particularly useful when working with (liquid) biopsies
from non-resectable stage III and IV patients due to the reduced
number of cells that are typically obtained. Such low volumes also
present the added benefit of being more affordable, a critical
consideration for clinical implementation. Consistency and
reproducibility of the gels at different volumes and for different
co-assembling matrices should also be confirmed to ensure reli-
able results in any potential translational applications. More
widespread availability and GMP certification of commercially
available peptides should also help establish their consistency at
the preclinical stage. Preliminary studies combining self-assembly
with biofabrication22 and microfluidics60 open the door to the
development of more advanced ex vivo models capable of
recreating, for example, vascular and neuroendocrine compo-
nents, which may further enhance the recapitulation of each
patient’s characteristic drug resistance. In particular, these
approaches may enable the modelling of cell-extrinsic resistance
mechanisms such as hypoxia and interstitial fluid pressure, which
are critical factors in PDAC drug response24. By linking various
co-assembled matrices representative of different tissues, such
approaches may also enable the study of metastatic dissemination
and homing. Control over the molecular and physical properties
of the cultures over time may also enhance the evaluation of
functional endpoints, such as invasion and stemness61.
In the future, we hope to obtain a more thorough under-
standing of the cancer cell populations in self-assembled cultures
as compared to their corresponding tumours (e.g., by single-cell
and spatial transcriptomics), as well as their metabolic status,
which should enable us to refine the system further and expand
our systematic comparison with models such as spheres and
organoids. Recently, in vivo experimentation has demonstrated
that the transcriptomic profile and progression of PDAC is
conditioned by the microenvironment62; reproducing these
findings ex vivo would also be of great value given the marked
heterogeneity of PDAC tumours. Ultimately, the major challenge
remaining is to establish the fidelity of the system across a wider
cohort of patients, especially in terms of drug resistance and
sensitivity. To ensure consistency, clinical and preclinical testing
with patients and patient-derived PA-ECM cultures should be
run in parallel as co-clinical trials63. Although, so far, such an
approach has been explored in mouse models only, it may
become a new standard for the validation of comprehensively
characterised ex vivo platforms like the one presented here.
Methods
Primary human tissue. Patient samples were collected through the ARC-Net
Biobank of the University and Hospital Trust of Verona approved by the Verona
University Hospital Ethics Committee (Program 1885 protocol 52,438 23/11/2010,
program 2172 protocol 26,773 23/05/2012; Supplementary Table 2). Informed
consent was obtained from all participants. Patient-derived xenografts (PDXs) were
produced under decree no. 107/2012-B and 108/2012-B by the Italian Ministry of
Health based on the legislative decree 106/92 regarding the protection of animals
used in scientific research. PDX tissues, grown subcutaneously in the flank of
immunodeficient NMRI:Foxn1nu/nu mice (Charles River, UK), were used to isolate
primary PDAC cells with 2% collagenase P (Roche, UK) and 1 mg/mL dispase (Life
Technologies, UK). Mice were housed in a dedicated facility at 24 °C with a 12-h
light/dark cycle and 50% humidity. Cells were grown in RPMI medium (Life
Technologies, UK) supplemented with 10% foetal bovine serum at 37 °C and 5%
CO2. For experiments, cells were maintained in sphere medium: DMEM/
F12 supplemented with 2% B27 (Life Technologies, UK), 20 ng/mL FGF2
(PeproTech, UK) and 2 mM L-glutamine (Life Technologies, UK), while organoids
were grown in organoid medium6. For multicellular cultures, PDAC cells were co-
cultured with primary PSCs isolated from PDAC patient-derived tissues collected
at the Technical University of Munich and approved by the Faculty of Medicine
Ethics Committee (ethical approval 5510/12), and with primary macrophages.
These were derived from circulating monocytes obtained from the blood of healthy
donors (REC reference 17/EE/0182) and polarised with CSF1 (20 ng/mL) for
5 days.
PA design and synthesis. E3 PA (C16-V3A3E3) was chosen due to its robust and
tuneable physical properties27, as well as its ability to co-assemble with ECM
molecules through electrostatic interactions (Fig. 1a) and to enable co-assembled
nanofibre alignment24. Other negatively-charged PAs exhibited weaker assembly,
while positively-charged PAs, such as K3 PA (C16-V3A3K3) were rejected due to
their ability to disrupt cell membranes64. E3 PA was produced by solid-phase
peptide synthesis as previously reported65. Further information is given in
the supplementary methods.
Cell culture in PA-ECM. E3 PA was dissolved in HEPES buffer (10 mM HEPES,
3 mM KCl, 150 mM NaCl) at pH 7.4 to a concentration of 10 mg/mL, transiently
heated to 80 °C for 30 min and mixed with cells to obtain hydrogels (2.5 × 104 cells/
cell type/5 µL hydrogel) as illustrated in Fig. 2a. For the assembly of the hydrogels,
a custom ECM solution was prepared by diluting collagen type I (Advanced Bio-
Matrix, USA) tenfold in HEPES buffer to a final concentration of 500 μg/mL,
followed by dilutions of fibronectin (50 μg/mL final concentration) (R&D Systems,
USA), laminin (50 μg/mL) (R&D Systems, USA), 10 kDa hyaluronan (500 μg/mL;
Lifecore, UK) and 1 MDa hyaluronan (500 μg/mL; Lifecore, UK). These ECM
macromolecules, in similar ratios (Supplementary Fig. 10), are known to be among
the most abundant in the PDAC ECM39. In 96-well plates, 5 μL PA cultures were
co-assembled with 50 μL of ECM. Alternatively, when evaluating the effects of
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paracrine factors or physical parameters on PA cultures, 20 μL of 20 mM CaCl2
were used as gelling solution to avoid the confounding biological effects of the
custom ECM components.
Characterisation of PA-ECM cultures. Cell viability was assessed using a live/
dead kit (Life Technologies, UK) and imaged on a Zeiss 710 confocal microscope.
For immunofluorescence imaging, samples were fixed in 4% paraformaldehyde,
permeabilized with 0.25% Triton X-100 and blocked with 5% bovine serum
albumin prior to antibody incubation (Supplementary Table 3). Z-stack images
were taken at 10 µm intervals over a distance of 250–350 µm and analysed on
ImageJ 1.52 u (NIH, USA). For gene expression analysis, total RNA was extracted
with TRI Reagent (Sigma-Aldrich, UK) and reverse-transcribed into cDNA using
the QuantiTect Reverse Transcription Kit (Qiagen, UK). qPCR was performed
using the PerfeCTa SYBR Green FastMix Low Rox (Quanta Biosciences, UK) and
gene-specific primers (Supplementary Table 4) on a QuantStudio 7 system
(Applied Biosystems, UK). Results were analysed with the comparative Ct method
and normalised to the expression of the housekeeping gene RPS13. Selected genes
were validated at the protein level by Western blot. Briefly, cell lysates were pre-
pared in RIPA buffer, separated by SDS-PAGE and blotted onto nitrocellulose
membranes. After blocking with 5% bovine serum albumin, primary antibodies
(Supplementary Table 3) were incubated overnight, followed by HRP-linked sec-
ondary antibodies and ECL Prime Western Blot Detection Reagent (GE Health-
care, USA). Chemiluminescence was detected on an Amersham Imager 600 (GE
Healthcare, USA).
Functional assays. The sphere-forming capacity of PDAC cells was evaluated
following established methods53 at a density of 1 × 103 cells/mL and quantified on a
CASY TTC counter (Innovatis, Switzerland). Migration was assessed by measuring
the scratch closure of monolayers cultured in 24-well plates (2 × 105 cells/well) after
exposure to hyaluronan for 20 h. Invasion was assayed in 0.8 µm pore-sized
transwell inserts (Life Technologies, UK) coated with 70 µL of collagen type I
(0.1 mg/mL). 5 × 104 cells were seeded per well and exposed to hyaluronan from
the lower chamber. After 24 h, cells were fixed, stained with DAPI and imaged.
Controls were run without hyaluronan and negative controls without foetal
bovine serum.
Transcriptomic analysis. PDAC cells were cultured for 7 days as 2D monolayers,
PA-ECM cultures, Matrigel-embedded organoids and sphere cultures and RNA
was extracted with the RNeasy mini kit (Qiagen, USA). Corresponding primary
and PDX tissue samples were dissociated prior to RNA extraction. mRNA was
enriched by polyA selection and transcriptomic analysis was performed on a
NovaSeq 6000 (Illumina, USA). FASTQ files were checked for quality with FastQC
and sortmerna was used to deplete rRNA from tissue-derived sequences. All
sequences were then mapped to the primary assembly of GENCODE 30 using
kallisto v0.45.0. Differential gene expression was analysed with DESeq2 and gene
set enrichment with GSEA 4.0.1.
Matrisome analysis. Matrix-enriched pellets from primary tumour, PDX, PA-
ECM and organoid samples were generated using the CNMCS compartmental
protein extraction kit (BioChain, US) and processed for mass spectrometry as
previously described66. Further details are given in the supplementary methods.
Peptides were detected on an LTQ-Orbitrap XL mass spectrometer (Thermo Sci-
entific, USA). For protein identification, Mascot searches were run against the
human Swiss-Prot database (PDX and organoid samples were also searched against
the murine dataset), while PESCAL was used to calculate relative protein abun-
dances (Supplementary Data 2).
In vivo implantation of cell-laden hydrogels. PDAC cells (5 × 104 – 2 × 105) were
cultured for 7 days in PA-ECM and organoid conditions, respectively, and then
subcutaneously implanted into the flanks of female immunodeficient NMRI:-
Foxn1nu/nu mice (n= 6/per group). Cell-free PA-ECM served as control. Tumour
dimensions were measured with a calliper and volume was calculated using the
formula (width2 × length)/2, where length is the longest dimension. After 9 weeks,
when tumours reached a palpable size (>250–300 mm3), necropsy was performed,
and tissues were processed for histology and immunohistochemistry. Procedures
were conducted in accordance with institutional and national regulations (Animals
in Science Regulation Unit, Home Office Science, London, UK; project license PPL
70/8129).
In vitro drug testing. PDAC mono- and multicellular cultures were grown in PA-
ECM, organoid, sphere and 2D adherent conditions for 7 days and then treated
with gemcitabine (100 ng/mL) and nab-paclitaxel (10 µM), alone or in combina-
tion, as well as triptolide (25 nM), for another 3 days (flow cytometry) or
7 days (IHC).
Flow cytometry. Cells were extracted by dissociating PA-ECM hydrogels, orga-
noids, spheres and 2D monolayers in TrypLE Express (Gibco, USA) with a
micropipette. Samples were normalised to 106 cells/mL, blocked with Flebogamma
(Grifols, Spain) and incubated with primary antibodies (Supplementary Table 3).
For cell cycle analysis, cells were fixed with 4% paraformaldehyde, permeabilized
with 0.25% Triton X-100 and stained with DAPI (10 µg/mL). Cells were analysed
on an LSR Fortessa cell analyser (BD Biosciences, USA) and gated to exclude debris
and doublets (Supplementary Fig. 11).
Histology and immunohistochemistry. Primary tumour, PDX and PA-ECM
samples were fixed in 4% paraformaldehyde and embedded in paraffin (hydrogel
replicates were combined into one agarose gel prior to embedding). Samples were
sectioned (5 µm), mounted onto glass slides, deparaffinized with xylene and
rehydrated. Antigen retrieval was performed at 95 °C in sodium citrate buffer.
Sample morphology was examined by Mayer’s haematoxylin and eosin staining.
Proteins were detected using primary antibodies (Supplementary Table 3), followed
by HRP-conjugated secondary antibodies (Dako, USA), diaminobenzidine and
Mayer’s haematoxylin counterstaining. Hyaluronan was stained with biotin-
conjugated HABP2 and specificity was confirmed with hyaluronidase (50 units;
Sigma-Aldrich, US) as previously reported67. Pentachrome staining was performed
as previously reported68. Samples were imaged on a Pannoramic 250 Flash III
scanner (3DHISTECH, Hungary). To evaluate drug response, the intensity of
staining was automatically scored into four categories (negative, weak, moderate,
strong) and calculated thus: H-score= [1 × (% area “weak”) + 2 × (% area
“moderate”) + 3 × (% area “strong”)].
Statistics and reproducibility. Data are shown as mean ± standard deviation,
unless otherwise specified. Multiple comparisons were performed by one-way or
two-way ANOVA with Bonferroni correction in Prism 7.05 (GraphPad, USA); the
significance threshold was set at p ≤ 0.05 (Supplementary Data 3). Heatmaps,
principal component analysis and linear regression plots were generated in R 3.5.3
(R Foundation, USA). The electron micrographs in Fig. 2b–e are representative of
three independently synthesised hydrogels per condition. The micrographs in
Fig. 2b–i are representative of over 100 cell-laden hydrogels prepared over a 4-year
period. The histology images in Fig. 4f and Supplementary Fig. S3c are repre-
sentative of three independent in vivo experiments. The brightfield micrographs in
Fig. 5h are representative of three independent experiments using cells from two
different patients. The ex vivo histology images in Fig. 8a are representative of three
independent experiments using cells from three different patients. The H&E
images in Supplementary Fig. 1d are representative of four individual gels per
timepoint and condition. The confocal images in Supplementary Fig. 1e are
representative of 16 individual gels. The brightfield images in Supplementary
Fig. 1h are representative of at least 10 samples per condition. The confocal images
in Supplementary Fig. 4d are representative of three samples per condition. The
confocal image in Supplementary Fig. 5b is representative of three independent
experiments. The IHC image in Supplementary Fig. 5e is representative of co-
cultures with samples from three different patients. The histology images in Sup-
plementary Fig. 5f are representative of tumours from four different patients. The
epifluorescence images in Supplementary Fig. 5h are representative of five inde-
pendent experiments. The histology images in Supplementary Fig. 6a and Sup-
plementary Fig. 7 are representative areas from 5 × 5mm tumour pieces. The H&E
images in Supplementary Fig. 9a are representative of five individual experiments
with cells from five different patients.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Raw and processed transcriptomic data are available at the GEO database under accession
number GSE139184. Proteomic data are available at the PRIDE database under accession
number PXD013254. All data that support the findings of this study are available within the
Article, Supplementary information and Source data file. Source data are provided with
this paper.
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